Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
Vancouver, Canada, July 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder (“AUD”), addiction, and weight management, today announced the filing of a patent application with the Hong Kong Patent Office for innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder (“PTSD”) and other mental health disorder
Vancouver, Canada, July 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder (“AUD”), addiction, and weight management, today announced the filing of a patent application with the Hong Kong Patent Office for innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder (“PTSD”) and other mental health disorders.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.